UK markets closed

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.0950-0.0450 (-3.95%)
As of 02:18PM EDT. Market open.
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-113,871
-113,871
-165,456
-158,090
-130,092
Depreciation & amortisation
9,840
9,840
6,075
6,567
7,594
Stock-based compensation
11,773
11,773
18,240
20,629
10,414
Change in working capital
-24,952
-24,952
-1,531
134,634
56,045
Other working capital
-145,760
-145,760
-171,509
1,948
-56,497
Other non-cash items
-21,882
-21,882
816
1,173
-55
Net cash provided by operating activities
-140,880
-140,880
-141,769
10,729
-53,591
Cash flows from investing activities
Investments in property, plant and equipment
-4,880
-4,880
-29,740
-8,781
-2,906
Purchases of investments
-75,953
-75,953
-48,117
-139,762
-381,040
Sales/maturities of investments
210,983
210,983
166,994
224,343
105,022
Other investing activities
1,124
1,124
-
-
-
Net cash used for investing activities
176,538
176,538
89,137
75,800
-278,924
Cash flows from financing activities
Common stock issued
624
624
12,817
2,529
334,388
Net cash used provided by (used for) financing activities
880
880
12,867
3,288
340,051
Net change in cash
37,415
37,415
-42,064
90,182
6,576
Cash at beginning of period
109,602
109,602
151,666
61,484
54,908
Cash at end of period
147,017
147,017
109,602
151,666
61,484
Free cash flow
Operating cash flow
-140,880
-140,880
-141,769
10,729
-53,591
Capital expenditure
-4,880
-4,880
-29,740
-8,781
-2,906
Free cash flow
-145,760
-145,760
-171,509
1,948
-56,497